AZR-BL-007

AZR-BL-007 is a preclinical-stage therapeutic candidate being developed by Azura Ophthalmics for the treatment of posterior blepharitis. Posterior blepharitis is a chronic inflammatory condition of the eyelids often associated with Meibomian Gland Dysfunction (MGD), characterized by the obstruction of meibomian glands by keratinized material. While specific details regarding the active ingredient of AZR-BL-007 have not been fully disclosed, it is part of Azura's portfolio which utilizes a keratolytic platform. This approach is designed to soften and remove keratin plugs at the gland orifice, thereby restoring the flow of meibum, stabilizing the tear film, and reducing the ocular surface inflammation and discomfort typical of blepharitis.